DOK7 congenital myasthenic syndrome

Area of Science:

• Neurology
• Genetics
• Molecular Biology

Background:

• Congenital myasthenic syndrome (CMS) encompasses various genetic disorders affecting neuromuscular transmission.
• DOK7 CMS, a relatively recent discovery, is the third most prevalent form of CMS in the UK.
• DOK7 protein is crucial for acetylcholine receptor (AChR) clustering at the postsynaptic membrane.

Purpose of the Study:

• To describe the clinical phenotype, diagnostic clues, and treatment outcomes of DOK7 CMS.
• To differentiate DOK7 CMS from other forms of CMS based on clinical presentation and response to treatment.

Main Methods:

• Clinical case review and analysis of patient data.
• Review of diagnostic criteria and genetic findings related to DOK7 mutations.
• Assessment of treatment efficacy with ephedrine and salbutamol.

Main Results:

• DOK7 CMS typically presents with limb girdle weakness and nonspecific myopathic features, often with onset between ages two and three.
• Eye movements are usually spared, and anticholinesterases may worsen weakness.
• Stridor in early-onset cases and tongue wasting can be indicative clues.
• Adult-onset worsening, particularly affecting bulbar and respiratory function, is common.
• Treatment with ephedrine or oral salbutamol shows slow but significant improvement over months.

Conclusions:

• DOK7 CMS has a distinct clinical profile that aids in diagnosis.
• Prompt identification and management with specific treatments like ephedrine or salbutamol can lead to substantial functional recovery.
• Understanding DOK7 CMS is vital for improving patient outcomes in congenital myasthenic syndromes.